Abstract Remarkable advances have been made with prolonged antihypertensive therapy m reversing cardiovascular morb&y and mortahty Deaths from stroke have been reduced by 70% and from coronary heart disease by 35% In contrast, endstage renal disease resulting from hypertension continues to mcrease The explanations for this seeming paradox remam unresolved even though experimental models have demonstrated that certain antihypertensive agents may have beneficial renal and mtrarenal hemodynamlc effects, but reversal of the mtrarenal pathological lesions have not been shown to improve This dlscusSion summarizes recent studies from our laboratory m aged (73-and 85-week-old) spontaneously hypertensive rats (SHR) with naturally occurring end-stage renal &ease and m a model of aged SHR employing mtrlc oxide mhlbition m younger, adult (20-week-old) SHR Our findings demonstrated that the systemic and whole renal hemodynatmcs, intrarenal glomerular dynamics, protemuna, and renal pathological lesions can be prevented or reversed with angiotensm-converting enzyme mlubltlon therapy but not with hydrochlorotlnazlde (at similar levels of arterial pressure reduction) The lmphcatlons and possible mechamsms mvolved m the development of both naturally occurrmg and nitric oxide-exacerbated SHR are multifactorial, mvolvmg the endothehal mtrlc oxide system and Its mteractlon with anglotensm II (and possibly bradykmm) among other factors Moreover, these pathophysiological cellular mechamsms may be shared by the aging process as well as m naturally occurrmg spontaneous hypertenslon m the rat and, perhaps, m humans with essential hypertension Thus, antihypertensive therapy seems to be specific m its ability to prevent and even reverse the pathophyslologlcal derangements of renal mvolvement m hypertension Thus, prevention and reversal of end-stage renal disease do not seem to require greater reduction of arterial pressure than with other target-organ mvolvement However, they do require specific mhlbition of the artenolar and glomerular lesions produced by the disease (Hypertension. 1997 
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Renal Involvement in Hypertension
The remarkable effects of antlhypertenslve drug therapy on the reversal of target-organ mvolvement from hypertension 1s a classic success story m hypertension Outcome analyses have clearly demonstrated the remarkable effects of prolonged antihypertensive therapy on reducing the morbidity and mortality of hypertensive vascular disease from stroke and coronary heart disease 6.7 Not usually commented upon m this context, at least as a follow-up thought, 1s the additional well-known observation that as the foregoing dramatic reductions m deaths from stroke (by upwards of 70%) and from coronary heart disease (by 35%) have contmued, there has been an unrelenting increase in the numbers of patients with hypertension progressing to ESRD 89 This is a tremendously dlsturbmg statlstlc, and it 1s all the more unsatlsfymg because it leaves hypertension researchers (fundamental as well as clinical) without a satlsfymg explanation for this devastating and costly world-wide observation that, at present, defies explanation 10 Nephrologists concerned with this seeming paradox have thus far provided no credltable rationale for the continued rise m patients with ESRD (Fig l) Selected Abbreviations and Acronyms ACE = anglotensm-convertmg enzyme Ang II = anglotensm II ESRD = end-stage renal disease L-NAME = N"-mtro+argmme methyl ester NO = nltnc oxide SHR = spontaneously hypertensive rat(s) therapeuttc classes used thus far m the long term and controlled chmcal trrals that have demonstrated reductions m morbldrty and mortality from stroke and coronary heart disease were not specific enough for the kidney Supportmg these contentions are the unwavering long-term eptdemiologrcal data of the past 20 years.9 This IS not to say that every patient progressing mto ESRD does so from long-standing essential hypertension; but the vast maJortty of patients are hypertensive and are erther black or have coexlstmg diabetes melhtus (Fig 2) 9 Background Experimental Studies
In recent years, a number of experimental models have been developed for producing ESRD. In brief, they have usually mvolved mductron of renal failure with unilateral nephrectomy and extirpation of contralateral renal tissue with or without addrtronal salt loading, sterotdal admmlstratlon, renal infarction, or admmistratlon of nephrotoxtc drugs or chemrcals None of these studies, however, have involved the natural development of renal failure m ammals with genetic hypertension Clearly, and of great chnma1 relevance, these models cannot be considered to be analogous to the patient with essential hypertension who progresses slowly (or even, on rarer occasrons, rapidly) mto chrome renal failure Despite thus rather frustrating picture, these studies have led to a very useful hypothesis of the potential dynamics that might be mvolved with the help of carefully performed renal mrcropuncture analyses Thus, these models of hypertension and renal disease have demonstrated that the renal mvolvement m hypertension is associated with both afferent and efferent glomerular artenolar constrrcnon, glomerular hypertension and hyperfiltratlon, leakage of protein molecules across the glomerular capillary wall, progressrve glomerulosclerosls, and ultimately renal funcbona1 deterroratron [11] [12] [13] In our earlier micropuncture studies mvolvmg the 20-to 23-week-old male SHR, we demonstrated abnormal responsiveness of the SHR afferent and glomerular arterioles to a-adrenergrc stimulation and mhrbitionr4J5 as well as to improve renal and glomerular dynamics after acute or prolonged administration of a calcmm antagonist or an ACE mhrbttor.r6-18 However, these relatively younger SHR did not exhibit any evidence of mcreased efferent arterlolar resistance, elevated glomerular hydrostatrc pressure, or protemuria, r6-lq which had been postulated earlier. 11-13 Therefore, armed with the knowledge that when the SHR becomes 1 year old, it naturally develops marked protemuna and rmpan-ed renal excretory functron that IS associated with pathologrcal evidence of glomerular inJury,20Jl we embarked on a series of studies that provide the substance of this lecture But, before describing those studies, a word IS necessary concernmg the rationale for this protocol Over the past 15 or so years, we had reported a series of studies on another target-organ involvement from hypertension-the pharmacologrcal reversal of increased left ventricular mass in the SHR.22123 Each of those studies mvolved the mterventron of a pharmacologtcal agent for a period of 3 weeks m male, adult SHR 20 to 23 weeks old Those studies demonstrated from the outset that certain classes of pharmacologrcal agents for 3 weeks were sufficient to reduce left ventricular mass Most important, we had selected the 3-week period of treatment because we had postulated earlier that partlcrpatmg m the development and reversal of left ventricular hypertrophy (LVH) wete nonhemodynamtc and hemodynamrc factors.*4 If early reversal of LVH were demonstrated, rt would be likely to be independent of hemodynamtc factors of pressure and afterload reductton.25 Thus, the followmg studies concerned with renal mvolvement m hypertension were similarly desrgned to determme whether antihypertensive therapy for 3 weeks would be effective m reversing the renal pathological lesions as well as the associated hemodynamrc and micropuncture glomerular dynamic defects
The SHR: A Model of Renal Involvement in a Genetic Form of Hypertension Naturally Occurring ESRD Having been satisfied that changes associated with naturally occurrmg ESRD do, m fact, occur in the SHR,2"Jl we set aside a number of adult, male, 20-week-old SHR to age for 1 additional year after our usual study age of 20 weeks This would permit us to determine whether the systemic and renal hemodynamlcs as well as glomerular dynamic changes could be associated with that period of aging.26 These studres clearly demonstrated that by 73 weeks of age, the SHR (m contrast to its normotenstve Wrstar-Kyoto control of the same age and sex) developed severe glomerular hypertenston and rschemra associated with marked afferent and efferent artenolar constrictron, glomerular sclerosis and arterrolar fibrinold necrosis, and severe protemuna. Moreover, an equal number of male httermates of these aged SHR, when treated with the same ACE mhrbrtor used earher m younger SHR, 18 stgmficantly reversed these marked systemrc and renal hemodynamrc and glomerular dynamrc alteratrons, as well as the assocrated pathologrcal lessons and the severe protemurra within the 3-week treatment.26 L-NAME Model for the 73-Week-Old SHR determined whether the changes affected by the additional year of aging could be accelerated by 3 weeks of NO synthase enzymatic inhibition.27 NO had been shown earlier to be the major source of the endothelium-derived relaxing factor that plays a critical role in local circulatory control, even in the kidney.28."1 Moreover, other studies had shown that responses to endothelium-dependent vasodilators were impaired in the SHR, possibly the result of reduced endothelium-derived NO or increased endothelium-derived constricting factor.32. 35 We therefore determined whether inhibition of the synthesis of endothelium-derived NO in the 20-to 23-week-old SHR might mimic the findings that we had demonstrated in the aged SHR with naturally developing ESRD.27 To test this hypothesis, we inhibited the synthesis of endothelium-derived NO with L-NAME for 3 weeks (50 mg/L drinking water prepared freshly each day). These studies demonstrated that the L-NAME produced marked proteinuria associated pathologically with severe hypertensive nephrosclerosis that was manifested physiologically by intense afferent glomerular arteriolar constriction with severe afferent arteriolar fibrinoid necrosis, segmental glomerular hyalinosis and sclerosis, and renal ischemia.27 Significant efferent glomerular arteriolar constriction was also produced but occurred without development of glomerular hypertension because of the more intense afferent arteriolar constriction that was associated with a significantly reduced renal blood flow and single nephron plasma flow. Thus, the 3-week intervention period with L-NAME mimicked the renal and intrarenal hemodynamic and glomerular dynamic alterations as well as the pathological and proteinuric findings we had observed earlier in the 73-week-old SHR (Figs 3 through 6) .26,27
Pharmacological Interventions
Next, it was of interest to know whether treatment with the same ACE inhibitor that we had used in the earlier two studies'8.26 would reverse the renal alterations that were associated earlier with L-NAME. To accomplish this, the same ACE inhibitor was administered either for 3 weeks contemporaneously with the L-NAME (a prevention intervention) or after the 3-week L-NAME treatment (a reversal intervention). These studies demonstrated that the cotreatment as well as the posttreatment 'with that ACE inhibitor did in fact produce equivalent reductions in arterial pressure and total peripheral resistance that were associated with significant decreases in both afferent and efferent arteriolar resistances, nephrosclerosis pathological scores (of both the glomeruli and the arterioles), and 24-hour urinary protein excretion.36 Most notably, ACE inhibition cotreatment with L-NAME completely prevented the renal glomerular hemodynamic alterations associated with L-NAME, and when it was given immediately after the L-NAME, it also reversed the glomerular injury scores that were observed in the same SHR earlier by renal biopsy following L-NAME. These changes were also associated with reduced smooth muscle a-actin deposition (by immunochemistry). Thus, these data demonstrated that ACE inhibition not only prevented but also reversed the L-NAME-exacerbated severe nephrosclerosis in the SHR, as indicated by improved systemic and renal hemodynamic, glomerular dynamic, proteinuric, and pathological alterations.36 In contrast to the foregoing findings with the ACE inhibitor were our very recent observations with the daily administration (by gastric gavage) of hydrochlorothiazide administered for 3 weeks following the 3-week L-NAME period of treatment.37 In these studies, the diuretic achieved a reduction in arterial pressure similar to that produced by the ACE inhibitor; however, renal micropuncture studies revealed an increased glomerular capillary pressure that was associated with a further increase in efferent (but unchanged afferent) glomerular arteriolar resistance as compared with the L-NAME control SHR group. Furthermore, the thiazide diuretic significantly increased the glomerular injury score further (without affecting the arteriolar injury score) that was also associated with a further increase in urinary protein excretion. The pathological studies showed further that the increased glomerular hydrostatic pressure was associated with more severe glomerulosclerosis associated with increased fibronectin and smooth muscle cw-actin deposition. Thus, our pharmacological studies clearly demonstrated that whereas an ACE inhibitor could prevent and reverse the systemic and renal hemodynamic and glomerular dynamic alterations as well as the pathological renal lesions associated with naturally occurring and L-NAME-provoked ESRD in the SHR, the thiazide diuretic exacerbated the glomerular lesions as well as the hemodynamic, functional, and pathological indexes of the disease (Figs 3 through 6) .37
To provide further insight into the underlying mechanisms that could be involved with these changes, we administered L-arginine (2 g/L drinking water) for 3 weeks to U-week-old male SHR (not given L-NAME). Although these data have not yet been published, they have been presented at this meeting of the Council.38 The data demonstrated that the 3-week course of L-arginine treatment markedly reversed the severe naturally occurring nephrosclerosis in these rats as well as the cardiac and
Interpretation of the SHR Findings
The results of these studies strongly support the following three concepts. First, reversibility of ESRD secondary to naturally developing hypertension (or, for that matter, in L-NAME-exacerbated hypertension) in the SHR is possible with antihypertensive therapy. Second, the reversibility of systemic and renal hemodynamic as well as glomerular dynamic, pathological, and proteinuric alterations were not necessarily dependent on dramatic reductions in systolic or diastolic pressure any more than with other target-organ involvement. And third, the demonstrated pathophysiological reversibility seems to be more dependent on the mechanism of action of the antihypertensive drug or drugs employed and can be achieved in as short a time period as 3 weeks in the SHR. Indeed, this relatively shortterm reversibility had been shown earlier with the reduction of left ventricular mass (in the SHR), which pointed to the locally mediated nonhemodynamic mechanisms of the antihypertensive drugs.22.24 Thus, whether in the naturally occurring hypertension of the aged SHR or in the exacerbated hypertensive disease produced by NO inhibition in the endothelium of younger, but adult, SHR, impairment of the generation of Ang II (eg, with an ACE inhibitor) seemed to favor that reversibility.*6J6 In contrast, the thiazide diuretic, which enhances generation of Ang II through its stimulation of the renin-angiotensin systern,39 exacerbated the pathophysiological alterations of the renal disease. Since a local renin-angiotensin system seems to exist within the kidney,40-44 our findings in the SHR seem to favor the concept that progression of the hypertensive glomerular disease occurs in association with generation of Ang II despite a reduction of systemic arterial pressure similar to that which was also achieved by the ACE inhibitor.36337 Our experimental data at the least provide some tentative mechanistic explanations for the rise of ESRD in predisposed patients with hypertension who may be particularly susceptible to diuretic therapy. Nevertheless, it may not be appropriate at this time to suggest with firm conviction that Ang II was the sole pathogenetic factor responsible for the progression of the hypertensive renal disease since ACE inhibition alone or with NO interaction may also involve other local mechanisms such as the local generation of kinins or the secondary effects on other endothelium-derived factors in the kidney and elsewhere.34,35,45-51 To this end, our studies involving the inhibition of endothelially generated NO may also be coparticipants in the pathophysiological responses reported herein. Sufficient data are now available to support the thesis of a locally functioning renin-angiotensin system that may interact with an NO synthase-dependent system or other related endothelium-generated mechanisms.
That aging, per se, of the SHR may be analogous to suppression of the endothelium-derived generation of NO is supported by several lines of evidence. Thus, NO synthesis seems to be impaired in experimental animals and humans with agings2353 as well as secondarily in endothelium-related diseases such as hypercholesterolemia and atherosclerosis54.55 and essential hypertension.56-59 The present (and highly controlled) studies in the SHR with naturally developing hypertensive ESRD (or with L-NAMEexacerbated ESRD in the younger SHR) provide strong support for these potential mechanisms, and ongoing studies are being directed toward these concepts in our laboratory.
It is appropriate in this lecture that honors Arthur Corcoran and the investigative team that offered the multifactorial mechanistic explanation of hypertension (the "mosaic" of hypertension)60 to suggest a similar mechanism for the underlying factors associated with ESRD (Fig 7) . As with the causation of hypertension, this mosaic is not exhaustive but involves the interaction of other pathophysiological processes including those of the aging process, atherosclerosis, and diabetes mellitus. It also involves those specific factors related to race, growth, immune responses, and lipid metabolism as well as with the generation of NO, Ang II, free radicals, and other humoral and therapeutic agents. 
